1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2022-2028) 1.2.2 DNA 1.2.3 RNA 1.2.4 Others 1.3 Market by Application 1.3.1 Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2022-2028) 1.3.2 Mild Symptom Patient 1.3.3 Critically Ill Patient 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size 2.2 Novel Coronavirus (COVID-19) Vaccine Market Size by Regions 2.2.1 Novel Coronavirus (COVID-19) Vaccine Growth Rate by Regions (2022-2028) 2.2.2 Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2022-2028) 2.3 Industry Trends 2.3.1 Market Top Trends 2.3.2 Market Use Cases 3 Key Players 3.1 Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2022 & 2028) 3.2 Novel Coronavirus (COVID-19) Vaccine Key Players Headquarters and Area Served 3.3 Key Players Novel Coronavirus (COVID-19) Vaccine Product/Solution/Service 3.4 Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market 3.5 Mergers & Acquisitions, Expansion Plans 4 Breakdown by Type and by Application 4.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2022-2028) 4.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2022-2028) 5 North America 5.1 North America Novel Coronavirus (COVID-19) Vaccine Market Forecast (2022-2028) 5.2 Novel Coronavirus (COVID-19) Vaccine Key Players in North America 5.3 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type 5.4 North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application 6 Europe 6.1 Europe Novel Coronavirus (COVID-19) Vaccine Market Forecast (2022-2028) 6.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Europe 6.3 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type 6.4 Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application 7 Asia-Pacific 7.1 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Forecast (2022-2028) 7.2 Novel Coronavirus (COVID-19) Vaccine Key Players in Asia-Pacific 7.3 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Type 7.4 Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Application 8 Rest of World 8.1 Latin America 8.1.1 Latin America Novel Coronavirus (COVID-19) Vaccine Market Analysis 8.1.2 Key Players in Latin America 8.2 Middle East & Africa 8.2.1 Middle East & Africa Novel Coronavirus (COVID-19) Vaccine Market Analysis 8.2.2 Key Players in Middle East & Africa 9 International Player Profiles 9.1 Inovio Pharmaceuticals 9.1.1 Inovio Pharmaceuticals Company Details 9.1.2 Inovio Pharmaceuticals Description and Business Overview 9.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction 9.1.4 Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.1.5 Inovio Pharmaceuticals Recent Development 9.2 Takis Biotech (Evvivax) 9.2.1 Takis Biotech (Evvivax) Company Details 9.2.2 Takis Biotech (Evvivax) Description and Business Overview 9.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Introduction 9.2.4 Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.2.5 Takis Biotech (Evvivax) Recent Development 9.3 Zydus Cadila 9.3.1 Zydus Cadila Company Details 9.3.2 Zydus Cadila Description and Business Overview 9.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Introduction 9.3.4 Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.3.5 Zydus Cadila Recent Development 9.4 Codagenix, Inc. 9.4.1 Codagenix, Inc. Company Details 9.4.2 Codagenix, Inc. Description and Business Overview 9.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 9.4.4 Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.4.5 Codagenix, Inc. Recent Development 9.5 GeoVax, Inc. 9.5.1 GeoVax, Inc. Company Details 9.5.2 GeoVax, Inc. Description and Business Overview 9.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 9.5.4 GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.5.5 GeoVax, Inc. Recent Development 9.6 Bravovax 9.6.1 Bravovax Company Details 9.6.2 Bravovax Description and Business Overview 9.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Introduction 9.6.4 Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.6.5 Bravovax Recent Development 9.7 Janssen Pharmaceutical Companies 9.7.1 Janssen Pharmaceutical Companies Company Details 9.7.2 Janssen Pharmaceutical Companies Description and Business Overview 9.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Introduction 9.7.4 Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.7.5 Janssen Pharmaceutical Companies Recent Development 9.8 Altimmune 9.8.1 Altimmune Company Details 9.8.2 Altimmune Description and Business Overview 9.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Introduction 9.8.4 Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.8.5 Altimmune Recent Development 9.9 Vaxart 9.9.1 Vaxart Company Details 9.9.2 Vaxart Description and Business Overview 9.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Introduction 9.9.4 Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.9.5 Vaxart Recent Development 9.10 CanSino Biologics 9.10.1 CanSino Biologics Company Details 9.10.2 CanSino Biologics Description and Business Overview 9.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Introduction 9.10.4 CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.10.5 CanSino Biologics Recent Development 9.11 ExpreS2ion Biotechnologies ApS 9.11.1 ExpreS2ion Biotechnologies ApS Company Details 9.11.2 ExpreS2ion Biotechnologies ApS Description and Business Overview 9.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Introduction 9.11.4 ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.11.5 ExpreS2ion Biotechnologies ApS Recent Development 9.12 Clover Biopharmaceuticals 9.12.1 Clover Biopharmaceuticals Company Details 9.12.2 Clover Biopharmaceuticals Description and Business Overview 9.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Introduction 9.12.4 Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.12.5 Clover Biopharmaceuticals Recent Development 9.13 GSK 9.13.1 GSK Company Details 9.13.2 GSK Description and Business Overview 9.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Introduction 9.13.4 GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.13.5 GSK Recent Development 9.14 Vaxil Bio Ltd. 9.14.1 Vaxil Bio Ltd. Company Details 9.14.2 Vaxil Bio Ltd. Description and Business Overview 9.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Introduction 9.14.4 Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.14.5 Vaxil Bio Ltd. Recent Development 9.15 Generex 9.15.1 Generex Company Details 9.15.2 Generex Description and Business Overview 9.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Introduction 9.15.4 Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.15.5 Generex Recent Development 9.16 Novavax, Inc. 9.16.1 Company Details 9.16.2 Novavax, Inc. Description and Business Overview 9.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 9.16.4 Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.16.5 Novavax, Inc. Recent Development 9.17 Sanofi Pasteur 9.17.1 Sanofi Pasteur Company Details 9.17.2 Sanofi Pasteur Description and Business Overview 9.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Introduction 9.17.4 Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.17.5 Sanofi Pasteur Recent Development 9.18 Baylor 9.18.1 Baylor Company Details 9.18.2 Baylor Description and Business Overview 9.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Introduction 9.18.4 Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.18.5 Baylor Recent Development 9.19 iBio, Inc. 9.19.1 iBio, Inc. Company Details 9.19.2 iBio, Inc. Description and Business Overview 9.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 9.19.4 iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.19.5 iBio, Inc. Recent Development 9.20 Moderna, Inc. 9.20.1 Moderna, Inc. Company Details 9.20.2 Moderna, Inc. Description and Business Overview 9.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Introduction 9.20.4 Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.20.5 Moderna, Inc. Recent Development 9.21 Curevac 9.21.1 Curevac Company Details 9.21.2 Curevac Description and Business Overview 9.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Introduction 9.21.4 Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.21.5 Curevac Recent Development 9.22 ImmunoPrecise 9.22.1 ImmunoPrecise Company Details 9.22.2 ImmunoPrecise Description and Business Overview 9.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Introduction 9.22.4 ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business (2022 & 2028) 9.22.5 ImmunoPrecise Recent Development 10 Market Dynamics 10.1 Industry Trends 10.2 Market Drives 10.3 Market Challenges 10.4 Market Restraints 11 Key Findings in This Report 12 Appendix 12.1 Research Methodology 12.1.1 Methodology/Research Approach 12.1.2 Data Source 12.2 Disclaimer 12.3 Author Details

List of Tables Table 1. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth Rate by Type (2022-2028) (US$ Million) Table 2. Key Players of DNA Table 3. Key Players of RNA Table 4. Key Players of Others Table 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size Growth by Application (2022-2028) (US$ Million) Table 6. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Regions (2022-2028) (US$ Million) Table 7. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2022-2028) Table 8. Market Top Trends Table 9. Market Use Cases Table 10. Global Novel Coronavirus (COVID-19) Vaccine Revenue by Players (2022 & 2028) (US$ Million) Table 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players (2022 &2028) Table 12. Key Players Headquarters and Area Served Table 13. Key Players Novel Coronavirus (COVID-19) Vaccine Product/Solution/Service Table 14. Date of Enter into Novel Coronavirus (COVID-19) Vaccine Market Table 15. Mergers & Acquisitions, Expansion Plans Table 16. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2022-2028) (US$ Million) Table 17. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Type (2022-2028) Table 18. Global Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2022-2028) (US$ Million) Table 19. Global Novel Coronavirus (COVID-19) Vaccine Market Size Share by Application (2022-2028) Table 20. North America Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2022 & 2028) & (US$ Million) Table 21. North America Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2022 & 2028) Table 22. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2022-2028) (US$ Million) Table 23. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2022-2028) Table 24. North America Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2022-2028) (US$ Million) Table 25. North America Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2022-2028) Table 26. Europe Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2022 & 2028) & (US$ Million) Table 27. Europe Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2022 & 2028) Table 28. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2022-2028) (US$ Million) Table 29. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2022-2028) Table 30. Europe Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2022-2028) (US$ Million) Table 31. Europe Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2022-2028) Table 32. Asia-Pacific Key Players Novel Coronavirus (COVID-19) Vaccine Revenue (2022 & 2028) & (US$ Million) Table 33. Asia-Pacific Key Players Novel Coronavirus (COVID-19) Vaccine Market Share (2022 & 2028) Table 34. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Type (2022-2028) (US$ Million) Table 35. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Type (2022-2028) Table 36. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size by Application (2022-2028) (US$ Million) Table 37. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Share by Application (2022-2028) Table 38. Key Players in Latin America Table 39. Key Players in Middle East & Africa Table 40. Inovio Pharmaceuticals Company Details Table 41. Inovio Pharmaceuticals Description and Business Overview Table 42. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Table 43. Inovio Pharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 44. Inovio Pharmaceuticals Recent Development Table 45. Takis Biotech (Evvivax) Company Details Table 46. Takis Biotech (Evvivax) Description and Business Overview Table 47. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product Table 48. Takis Biotech (Evvivax) Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 49. Takis Biotech (Evvivax) Recent Development Table 50. Zydus Cadila Company Details Table 51. Zydus Cadila Description and Business Overview Table 52. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product Table 53. Zydus Cadila Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 54. Zydus Cadila Recent Development Table 55. Codagenix, Inc. Company Details Table 56. Codagenix, Inc. Description and Business Overview Table 57. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 58. Codagenix, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 59. Codagenix, Inc. Recent Development Table 60. GeoVax, Inc. Company Details Table 61. GeoVax, Inc. Description and Business Overview Table 62. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 63. GeoVax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 64. GeoVax, Inc. Recent Development Table 65. Bravovax Company Details Table 66. Bravovax Description and Business Overview Table 67. Bravovax Novel Coronavirus (COVID-19) Vaccine Product Table 68. Bravovax Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 69. Bravovax Recent Development Table 70. Janssen Pharmaceutical Companies Company Details Table 71. Janssen Pharmaceutical Companies Description and Business Overview Table 72. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product Table 73. Janssen Pharmaceutical Companies Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 74. Janssen Pharmaceutical Companies Recent Development Table 75. Altimmune Company Details Table 76. Altimmune Description and Business Overview Table 77. Altimmune Novel Coronavirus (COVID-19) Vaccine Product Table 78. Altimmune Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 79. Altimmune Recent Development Table 80. Vaxart Company Details Table 81. Vaxart Description and Business Overview Table 82. Vaxart Novel Coronavirus (COVID-19) Vaccine Product Table 83. Vaxart Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 84. Vaxart Recent Development Table 85. CanSino Biologics Company Details Table 86. CanSino Biologics Description and Business Overview Table 87. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product Table 88. CanSino Biologics Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 89. CanSino Biologics Recent Development Table 90. ExpreS2ion Biotechnologies ApS Company Details Table 91. ExpreS2ion Biotechnologies ApS Description and Business Overview Table 92. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product Table 93. ExpreS2ion Biotechnologies ApS Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 94. ExpreS2ion Biotechnologies ApS Recent Development Table 95. Clover Biopharmaceuticals Company Details Table 96. Clover Biopharmaceuticals Description and Business Overview Table 97. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Table 98. Clover Biopharmaceuticals Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 99. Clover Biopharmaceuticals Recent Development Table 100. GSK Company Details Table 101. GSK Description and Business Overview Table 102. GSK Novel Coronavirus (COVID-19) Vaccine Product Table 103. GSK Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 104. GSK Recent Development Table 105. Vaxil Bio Ltd. Company Details Table 106. Vaxil Bio Ltd. Description and Business Overview Table 107. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product Table 108. Vaxil Bio Ltd. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 109. Vaxil Bio Ltd. Recent Development Table 110. Generex Company Details Table 111. Generex Description and Business Overview Table 112. Generex Novel Coronavirus (COVID-19) Vaccine Product Table 113. Generex Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 114. Generex Recent Development Table 115. Novavax, Inc. Company Details Table 116. Novavax, Inc. Description and Business Overview Table 117. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 118. Novavax, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 119. Novavax, Inc. Recent Development Table 120. Sanofi Pasteur Company Details Table 121. Sanofi Pasteur Description and Business Overview Table 122. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product Table 123. Sanofi Pasteur Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 124. Sanofi Pasteur Recent Development Table 125. Baylor Company Details Table 126. Baylor Description and Business Overview Table 127. Baylor Novel Coronavirus (COVID-19) Vaccine Product Table 128. Baylor Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 129. Baylor Recent Development Table 130. iBio, Inc. Company Details Table 131. iBio, Inc. Description and Business Overview Table 132. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 133. iBio, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 134. iBio, Inc. Recent Development Table 135. Moderna, Inc. Company Details Table 136. Moderna, Inc. Description and Business Overview Table 137. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product Table 138. Moderna, Inc. Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 139. Moderna, Inc. Recent Development Table 140. Curevac Company Details Table 141. Curevac Description and Business Overview Table 142. Curevac Novel Coronavirus (COVID-19) Vaccine Product Table 143. Curevac Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 144. Curevac Recent Development Table 145. ImmunoPrecise Company Details Table 146. ImmunoPrecise Description and Business Overview Table 147. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product Table 148. ImmunoPrecise Revenue in Novel Coronavirus (COVID-19) Vaccine Business 2022 & 2028 Table 149. ImmunoPrecise Recent Development Table 150. Novel Coronavirus (COVID-19) Vaccine Market Trends Table 151. Novel Coronavirus (COVID-19) Vaccine Market Drivers Table 152. Novel Coronavirus (COVID-19) Vaccine Market Challenges Table 153. Novel Coronavirus (COVID-19) Vaccine Market Restraints Table 154. Research Programs/Design for This Report Table 155. Key Data Information from Secondary Sources Table 156. Key Data Information from Primary Sources List of Figures Figure 1. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Type in 2022 & 2028 Figure 2. DNA Features Figure 3. RNA Features Figure 4. Others Features Figure 5. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Application in 2022 & 2028 Figure 6. Mild Symptom Patient Case Studies Figure 7. Critically Ill Patient Case Studies Figure 8. Novel Coronavirus (COVID-19) Vaccine Report Years Considered Figure 9. Global Novel Coronavirus (COVID-19) Vaccine Market Size and Growth Rate (2022-2028) (US$ Million) Figure 10. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Regions (2022-2028) Figure 11. Global Novel Coronavirus (COVID-19) Vaccine Market Share by Players in 2021 Figure 12. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Type (2022-2028) Figure 13. Global Novel Coronavirus (COVID-19) Vaccine Market Size Market Share by Application (2022-2028) Figure 14. Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share by Application in 2021 Figure 15. North America Novel Coronavirus (COVID-19) Vaccine Market Size 2022-2028 (US$ Million) Figure 16. Europe Novel Coronavirus (COVID-19) Vaccine Market Size 2022-2028 (US$ Million) Figure 17. Asia-Pacific Novel Coronavirus (COVID-19) Vaccine Market Size 2022-2028 (US$ Million) Figure 18. Novel Coronavirus (COVID-19) Vaccine Market Size in Latin America (2022-2028) (US$ Million) Figure 19. Novel Coronavirus (COVID-19) Vaccine Market Size in Middle East & Africa (2022-2028) (US$ Million) Figure 20. Bottom-up and Top-down Approaches for This Report Figure 21. Data Triangulation Figure 22. Key Executives Interviewed

Inovio Pharmaceuticals Takis Biotech (Evvivax) Zydus Cadila Codagenix, Inc. GeoVax, Inc. Bravovax Janssen Pharmaceutical Companies Altimmune Vaxart CanSino Biologics ExpreS2ion Biotechnologies ApS Clover Biopharmaceuticals GSK Vaxil Bio Ltd. Generex Novavax, Inc. Sanofi Pasteur Baylor iBio, Inc. Moderna, Inc. Curevac ImmunoPrecise